10x Genomics, Inc. TXG
Our mission is to accelerate the mastery of biology to advance human health. We are a life sciences technology company focused on building innovative products and solutions to interrogate, understand and master biology. Our integrated research solutions include instruments, consumables and software for analyzing biological systems at a resolution and scale that matches the complexity of biology. We have built deep expertise across diverse disciplines including chemistry, biology, hardware and software. Innovations in all of these areas have enabled the deployment of our rapidly expanding suite of products, which allow our customers to interrogate biological systems at previously inaccessible resolution and scale. Our products have enabled researchers to make fundamental discoveries across multiple areas of biology, including oncology, immunology and neuroscience.
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $642.8M | $610.8M | $618.7M | $516.4M | $490.5M | $298.8M | $245.9M | $146.3M | $71.1M | — |
| Cost of revenue | $198.9M | $196.3M | $209.4M | $120.4M | $74.1M | $58.5M | $61.0M | $28.7M | $10.6M | — |
| Gross profit | $443.9M | $414.5M | $409.3M | $396.0M | $416.4M | $240.4M | $184.9M | $117.7M | $60.5M | — |
| SG&A | $316.1M | $344.3M | $343.3M | $298.3M | $257.6M | $202.3M | $130.8M | $87.9M | $46.7M | — |
| Total operating expenses | $504.9M | $609.0M | $674.6M | $564.0M | $468.7M | $774.5M | $215.4M | $228.4M | $78.9M | — |
| Operating income | -$61.0M | -$194.6M | -$265.3M | -$167.9M | -$52.3M | -$534.1M | -$30.6M | -$110.8M | -$18.4M | — |
| Interest expense | $0 | $4.0K | $33.0K | $476.0K | $866.0K | $1.7M | $3.1M | $2.4M | $811.0K | — |
| Pre-tax income | -$39.9M | -$177.7M | -$248.8M | -$162.0M | -$53.7M | -$534.5M | -$31.0M | -$112.4M | -$18.7M | — |
| Income tax | $3.6M | $4.9M | $6.3M | $4.0M | $4.5M | $8.3M | $218.0K | $87.0K | $21.0K | — |
| Net income | -$43.5M | -$182.6M | -$255.1M | -$166.0M | -$58.2M | -$542.7M | -$31.3M | -$112.5M | -$18.8M | — |
| EPS, basic | -0.35 | -1.52 | -2.18 | -1.46 | -0.53 | -5.37 | -0.80 | — | — | — |
| EPS, diluted | -0.35 | -1.52 | -2.18 | -1.46 | -0.53 | -5.37 | -0.80 | -8.40 | -1.62 | — |
| Shares, diluted (wtd. avg.) | $124.7M | $120.5M | $117.2M | $113.9M | $110.3M | $101.2M | $39.1M | — | — | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $474.0M | $344.1M | $359.3M | $227.4M | $596.1M | $688.6M | $476.5M | $70.1M | $47.9M | $41.7M |
| Short-term investments | $49.4M | $49.3M | $29.4M | $210.2M | $0 | — | — | — | — | — |
| Receivables | $47.0M | $87.9M | $114.8M | $104.2M | $85.3M | $51.2M | $33.4M | $28.1M | — | — |
| Inventory | $56.3M | $83.1M | $73.7M | $81.6M | $60.0M | $30.0M | $15.3M | $8.6M | — | — |
| Total current assets | $684.5M | $584.4M | $596.0M | $635.0M | $747.6M | $774.4M | $480.8M | $106.2M | — | — |
| Property, plant and equipment | $226.7M | $252.6M | $279.6M | $289.3M | $169.5M | $72.8M | $48.8M | $11.1M | — | — |
| Goodwill | $4.5M | $4.5M | $4.5M | $4.5M | $4.5M | $0 | — | — | — | — |
| Other intangibles | $62.3M | $15.7M | $16.6M | $22.9M | $25.4M | $22.4M | $22.4M | $642.0K | — | — |
| Total assets | $1.04B | $918.6M | $965.1M | $1.03B | $1.02B | $929.3M | $605.9M | $124.3M | — | — |
| Accounts payable | $12.7M | $12.9M | $15.7M | $21.6M | $17.4M | $4.7M | $13.0M | $8.8M | — | — |
| Short-term debt | — | — | — | — | — | $0 | $9.9M | $4.2M | — | — |
| Total current liabilities | $153.5M | $117.6M | $127.2M | $131.0M | $110.4M | $118.1M | $63.0M | $32.4M | — | — |
| Long-term debt | — | — | — | — | — | $0 | $19.8M | $25.5M | — | — |
| Total liabilities | $245.0M | $208.5M | $224.1M | $223.2M | $201.3M | $190.3M | $185.8M | $101.1M | — | — |
| Retained earnings | -$1.51B | -$1.47B | -$1.28B | -$1.03B | -$863.3M | -$805.1M | -$262.4M | -$231.1M | — | — |
| Total equity | $796.3M | $710.1M | $741.0M | $805.7M | $817.6M | $739.1M | $420.1M | -$220.0M | -$112.5M | -$96.4M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $136.1M | $6.7M | -$15.2M | -$33.6M | -$21.4M | -$217.9M | $34.6M | -$76.4M | -$10.7M | — |
| Depreciation and amortisation | $36.2M | $35.9M | $35.5M | $25.4M | $21.1M | $14.0M | $7.1M | $3.9M | $4.3M | — |
| Stock-based compensation | $109.1M | $140.7M | $166.9M | $136.8M | $96.0M | $48.6M | $13.3M | $2.7M | $1.7M | — |
| Capital expenditure | $5.9M | $12.4M | $48.6M | $131.7M | $101.3M | $36.7M | $42.7M | $6.3M | $3.8M | — |
| Investing cash flow | -$13.4M | -$32.6M | $133.5M | -$350.9M | -$106.7M | -$38.4M | -$42.8M | -$6.7M | -$3.8M | — |
| Financing cash flow | $6.8M | $10.9M | $13.7M | $15.8M | $35.3M | $468.9M | $414.6M | $105.4M | $20.6M | — |
| Buybacks | — | — | — | — | — | — | — | — | $80.0K | — |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001628280-26-027201.
Others in SIC 3826
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| A | AGILENT TECHNOLOGIES, INC. | $42.53B | 33.0x | 6.7% |
| WAT | WATERS CORP /DE/ | $40.22B | 38.0x | 7.0% |
| ILMN | ILLUMINA, INC. | $32.95B | 40.0x | -0.7% |
| MTD | METTLER TOLEDO INTERNATIONAL INC/ | $26.95B | 32.0x | 4.0% |
| RVTY | REVVITY, INC. | $14.53B | 62.9x | 3.7% |
| BIO | BIO-RAD LABORATORIES, INC. | $10.33B | 13.9x | 0.7% |
| AVTR | Avantor, Inc. | $10.22B | — | -3.4% |
| BRKR | BRUKER CORP | $8.88B | — | 2.1% |